Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer

World Journal of Surgical Oncology

Zhiguo Rao³  Junming Feng¹  Yong Zhao³  Bicheng Zhang³  Fuqiu Tang²  Bo Yang³ 

[1] Department of Pathology, Wuhan General Hospital of Guangzhou Command PLA, 627 Wuluo Road, Wuchang District, Wuhan 430070, China;Second Department of Cadres, Wuhan General Hospital of Guangzhou Command PLA, 627 Wuluo Road, Wuchang District, Wuhan 430070, P.R. China;Department of Oncology, Wuhan General Hospital of Guangzhou Command PLA, 627 Wuluo Road, Wuchang District, Wuhan 430070, P.R. China

关键词: Immunohistochemistry;    Colon cancer;    Matrix metalloproteinase-9;   

Others  :  820493
DOI  :  10.1186/1477-7819-12-24

 received in 2013-11-20, accepted in 2014-01-18,  发布年份 2014

【 摘 要 】

Background

Matrix metalloproteinase-9 (MMP-9) is an important member of the matrix metalloproteinase family and is considered to be involved in the invasion and metastasis of cancer cells. This study analyzed the expression of MMP-9 in colon cancer patients and the relationship between this expression and clinicopathological features and survival.

Methods

We immunohistochemically investigated 68 specimens of colon cancer tissues and corresponding distal normal mucosa tissues using MMP-9 antibody. Then, the correlation between MMP-9 expression and clinicopathological features and its prognostic relevance were determined.

Results

The expression rate of MMP-9 in colon cancer tissues was significantly higher than that in distal normal mucosa (69.1% versus 2.9%, P < 0.001). Significant correlations were only found between high levels of MMP-9 expression and metastasis of lymph nodes and Dukes’ stage. Overexpression of MMP-9 was associated with shorter survival times in univariate analysis. Multivariate analysis confirmed that MMP-9 expression was an independent prognostic factor.

Conclusions

MMP-9 is correlated with the metastasis of lymph nodes, and its elevated expression may be an adverse prognostic indicator for the patients of colon cancer.

【 授权许可】

   
2014 Yang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
• [2]Long N, Moore MA, Chen W, Gao CM, Lai MS, Mizoue T, Oyunchimeg D, Park S, Shin HR, Tajima K, Yoo KY, Sobue T: Cancer epidemiology and control in north-east Asia - past, present and future. Asian Pac J Cancer Prev 2010, 11(Suppl 2):107-148.
• [3]Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000, 2:252-257. BioMed Central Full Text
• [4]Stetler-Stevenson WG, Yu AE: Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001, 11:143-152.
• [5]Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA: Molecular aspects of tumor cell invasion and metastasis. Cancer 1993, 71:1368-1383.
• [6]Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM, Sutherland G, Edwards DR: Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999, 79:1828-1835.
• [7]Groblewska M, Siewko M, Mroczko B, Szmitkowski M: The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol 2012, 50:12-19.
• [8]Kyriakos M: The President’s cancer, the Dukes classification, and confusion. Arch Pathol Lab Med 1985, 109:1063-1066.
• [9]Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI: Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004, 10:8229-8234.
• [10]Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon T, Jansen EH, Slimani N, Byrnes G, Rinaldi S, Tjonneland A, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Kaaks R, Linseisen J, Boeing H, Bergmann MM, Trichopoulou A, Misirli G, Trichopoulos D, Berrino F, Vineis P, Panico S, Palli D, Tumino R, Ros MM, van Gils CH, et al.: Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations:a nested case–control study. BMJ 2010, 340:b5500.
• [11]Westermarck J, Kahari VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13:781-792.
• [12]Murphy G, Docherty AJ: The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992, 7:120-125.
• [13]Koukos G, Polytarchou C, Kaplan JL, Morley-Fletcher A, Gras-Miralles B, Kokkotou E, Baril-Dore M, Pothoulakis C, Harland SW, Iliopoulos D: MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with Ulcerative colitis. Gastroenterology 2013, 145:842-852.
• [14]Wang J, Liu L, Qiu H, Zhang X, Guo W, Chen W, Tian Y, Fu L, Shi D, Cheng J, Huang W, Deng W: Ursolic Acid simultaneously targets multiple signaling pathways to suppress proliferation and induce apoptosis in colon cancer cells. PLoS One 2013, 8:e63872.
• [15]Obata S, Goi T, Nakazawa T, Kimura Y, Katayama K, Yamaguchi A: Changes in CO2 concentration increase the invasive ability of colon cancer cells. Anticancer Res 2013, 33:1881-1885.
• [16]Gao J, Ding F, Liu Q, Yao Y: Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem 2013, 376:21-32.
• [17]Li D, Sun X, Yan D, Huang J, Luo Q, Tang H, Peng Z: Piwil2 modulates the proliferation and metastasis of colon cancer via regulation of matrix metallopeptidase 9 transcriptional activity. Exp Biol Med (Maywood) 2012, 237:1231-1240.
• [18]Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007, 8:221-233.
• [19]Colovic Z, Pesutic-Pisac V, Poljak NK, Racic G, Cikojevic D, Kontic M: Expression of matrix metalloproteinase-9 in patients with squamous cell carcinoma of the larynx. Coll Antropol 2013, 37:151-155.
• [20]Ryzhakova OS, Zavalishina LE, Andreeva I, Solov’eva NI: Interstitial collagenase, gelatinases A and B and their endogenous inhibitors in squamous cell cervical carcinomas. Biomed Khim 2013, 59:55-64.
• [21]Wang WL, Chang WL, Yeh YC, Lee CT, Chang CY, Lin JT, Sheu BS: Concomitantly elevated serum matrix metalloproteinases 3 and 9 can predict survival of synchronous squamous cell carcinoma of the upper aero-digestive tract. Mol Carcinog 2013, 52:438-445.
• [22]Sung H, Choi JY, Lee SA, Lee KM, Han S, Jeon S, Song M, Lee Y, Park SK, Yoo KY, Noh DY, Ahn SH, Kang D: The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer. BMC Cancer 2012, 12:193. BioMed Central Full Text
• [23]Unsal D, Akyurek N, Uner A, Erpolat OP, Han U, Akmansu M, Mentes BB, Dursun A: Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. Am J Clin Oncol 2008, 31:55-63.